Guru Ownership Trend
Guru Analysis for Zentalis Pharmaceuticals, Inc. (ZNTL)
Zentalis Pharmaceuticals, Inc. (ZNTL), a key player in the Healthcare sector, continues to attract institutional attention.
As of Q1 2026, a total of 4 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $8.49 M.
Top institutional holders include Renaissance Technologies (RenTech) and Steven Cohen.
Institutional sentiment is currently Slightly Bearish. This is evidenced by a $2.28 M net outflow during the quarter.
On the selling side, Cliff Asness reduced exposure by 50.7%.
Key Holders
Top 5 by Value
Top 5 by Conviction
Recent Activity Breakdown (Q1 2026)
Guru Consensus (Q1 2026)
FAQs for Zentalis Pharmaceuticals, Inc. (ZNTL)
Major holders include Renaissance Technologies (RenTech) ($4.54 M), Steven Cohen ($221,958), Paul Tudor Jones ($81,547). According to the latest reported data, 4 tracked investment managers collectively hold approximately 2.09 M shares.
According to the latest 13F reporting period, sentiment appears Bearish (Net Selling). There was a net outflow of $2.28 M, with 0 managers increasing positions and 3 managers reducing holdings.
During the most recent reporting period, 3 managers trimmed their positions, while 0 fully exited ZNTL. The total reported sell value was $2.28 M.
No tracked managers opened new positions or increased their holdings in ZNTL during the most recent reporting period.